Advances in the treatment of mania: Aripiprazole

Actas Espanolas de Psiquiatria

Volumn 36, Issue 3, 2008, Pages 158-164

  Vieta, E ^a,b   Franco, C ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Antipsychotics; Aripiprazole; Bipolar disorder; Lithium; Mania

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ACUTE DISEASE; BIPOLAR DISORDER; HUMAN; REVIEW;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; PIPERAZINES; QUINOLONES;

EID: 46249134046     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother 2005;5:297-307.
2. Davies MA, Sheffler DJ, Roth BL Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004;10:317-36.
3. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-93.
4. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-20.
5. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004;18:375-83.
6. Lyseng-Williamson KA, Perry CM. Aripiprazole: in acute mania associated with bipolar I disorder. CNS Drugs 2004;18: 367-76.
7. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003;60:974-7.
8. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006; 31:1854-63.
9. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005;45:89-93.
10. Vieta E, T'joen C, McQuade RD, Carson WH, Marcus RN, Sánchez R, et al. Efficacy od adjuntive aripiprazol to valproate or lithium in bipolar patients with mania who were partially non-responsive to valproate/lithium: a placebo-controlled study. Am J Psychiatry 2008 (en prensa).
11. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord 2005;7(Suppl. 4): 21-33.
12. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88.
13. Calabrese JR, Keck PE, Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60.
14. th APA Annual Meeting, Toronto, Canada NR 600, 2006.
15. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20.
16. Keck PE, Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
17. Sachs G, Sánchez R, Marcus R, Stock E, McQuade R, Carson W, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3 week placebo-controlled study. J Psychopharmacol 2006;20:536-46.
18. Garcia-Amador M, Pacchiarotti I, Valenti M, Sánchez RF, Goikolea JM, Vieta E. Role of aripiprazole in treating mood disorders. Expert Rev Neurother 2006;6:1777-83.
19. Vieta E, Bourin M, Sánchez R, Marcus R, Stock E, McQuade R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12 week trial. Br J Psychiatry 2005;187:235-42.
20. Keck PE, Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480-91.
21. Young AH, Oren DA, Lowy A, McQuade RD, Marcus RN, Carson WH, et al. Aripiprazol monotherapy in acute mania: a 12 week, randomized, placebo and haloperidol- controlled study, 2008.
22. Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, et al. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 2007; 12:683-9.
23. Keck PE, Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626-37.
24. Vieta E. Maintenance therapy for bipolar disorder: current and future management options. Expert Rev Neurother 2004;4: S35-42.
25. Colom F, Vieta E, Daban C, Pacchiarotti I, Sánchez-Moreno J. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 2006;93:13-7.
26. Rosa AR, Andreazza AC, Kunz M, Gomes F, Santin A, Sánchez-Moreno J, et al. Predominant polarity in bipolar disorder: diagnostic implications. J Affect Disord 2008;107:45-51.
27. Vieta E. Bipolar mixed states and their treatment. Expert Rev Neurother 2005;5:63-8.
28. Suppes T, Eudicone J, McQuade R, Pikalov A, III, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 2007.
29. Barbee JG, Conrad FJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004;16:189-94.
30. Papakostas Gl, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005;66:1326-30.
31. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonres-ponding patients with major depressive disorder. J Clin Psychiatry 2005;66:1216-20.
32. Potkin SG, Sana AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90.
33. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabet Care 2004;27:596-601.
34. Ali S, Pearlman RL, Upadhyay A, Patel P. Neuroleptic malignant syndrome with aripiprazole and lithium: a case report. J Clin Psychopharmacol 2006;26:434-6.
35. Palakurthi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clin Neuropharmacol 2007;30:47-51.
36. Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry 2006;18:169-72.
37. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005;66(Suppl. 5): 40-8.
38. Sachs GS, Gaulín BD, Gutiérrez-Esteinou R, McQuade RD, Pikalov A III, Pultz JA, et al. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatry 2007;68:1377-83.
39. Vieta E, Rosa AR. Evolving trends in the long-term treatment of bipolar disorder. World J Biol Psychiatry 2007;8:4-11.
40. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008; 32:675-92.
41. Vieta E, Pacchiarotti I, Scott J, Sánchez-Moreno J, Di Marzo S, Colom F. Evidence-based research on the efficacy of psychologic interventions in bipolar disorders: a critical review. Curr Psychiatry Rep 2005b;7:449-55.
42. Rosa AR, Sánchez-Moreno J, Martinez-Arán A, Salamero M, Torrent C, Reinares M, et al. Validity and reliability of the functioning assessment short test (FAST) in bipolar disorder. Clin Pract Epidemol Ment Health 2007b;3:5.